Core Viewpoint - BioVie Inc. has announced a public offering of 6,000,000 units at a price of $2.00 per unit, aiming to raise approximately $12 million for working capital and general corporate purposes [1][2]. Group 1: Offering Details - Each unit consists of one share of common stock and one warrant, with pre-funded units available [1]. - The gross proceeds from the offering are expected to be around $12 million before deducting underwriting discounts and commissions [1]. - The warrants will be immediately exercisable at an exercise price of $2.50 per share and will expire five years from issuance [1]. - The underwriter has a 45-day option to purchase up to an additional 900,000 shares or warrants to cover over-allotments [1]. Group 2: Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for chronic debilitating conditions, including liver disease and neurological disorders [5]. - The company's drug candidate bezisterim targets neuroinflammation and insulin resistance, which are significant factors in Alzheimer's and Parkinson's diseases [5]. - BioVie’s orphan drug candidate BIV201 is under evaluation for treating liver cirrhosis and ascites, with FDA Fast Track status [5].

Core Viewpoint - Ball Corporation has initiated a public offering of $750 million in Senior Notes due 2033, with the final terms dependent on market conditions [1] Group 1: Offering Details - The offering consists of $750 million aggregate principal amount of Senior Notes due 2033 [1] - The exact amount, terms, and timing of the offering will be influenced by market conditions and other factors [1] Group 2: Use of Proceeds - Ball plans to use the net proceeds for general corporate purposes, which may include refinancing or repaying debt [2] - A portion of the net proceeds will be used to repay outstanding borrowings under its U.S. dollar and multi-currency revolving credit facilities [2] Group 3: Management and Coordination - BofA Securities, Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., and Morgan Stanley & Co. LLC are acting as global coordinators and joint book-running managers for the offering [3] Group 4: Company Overview - Ball Corporation provides innovative and sustainable aluminum packaging solutions for various sectors, employing 16,000 people globally [6] - The company reported net sales of $11.80 billion for 2024, excluding its divested aerospace business [6]

Group 1 - Sana Biotechnology, Inc. has priced its underwritten public offering of 20,895,522 shares of common stock at $3.35 per share and pre-funded warrants to purchase 1,492,537 shares at $3.3499 per warrant [1] - The gross proceeds from the offering are expected to be approximately $75.0 million before deducting underwriting discounts and commissions [1] - The offering is expected to close on or about August 8, 2025, subject to customary closing conditions [1] Group 2 - Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the offering [2] - The offering is being made pursuant to a Registration Statement on Form S-3, which has been declared effective by the SEC [3] - A final prospectus supplement and accompanying prospectus will be filed with the SEC [3] Group 3 - Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients [5] - The company has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA [5]

Market Analysis - Figma's IPO highlights the need for improved public offering pricing processes [1] - The industry suggests that without better pricing, companies may seek alternative routes to the public market [1]

Core Viewpoint - Oxford Square Capital Corp. has announced a public offering of $65 million in unsecured notes with a 7.75% interest rate, maturing on July 31, 2030, with the option for early redemption starting July 31, 2027 [1][2]. Group 1: Offering Details - The offering is expected to close on August 7, 2025, and includes an option for underwriters to purchase an additional $9.75 million in notes [2]. - The notes will be listed on the NASDAQ Global Select Market under the trading symbol "OXSQH" [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to repay existing indebtedness, acquire investments, and for general corporate purposes [3]. Group 3: Company Overview - Oxford Square Capital Corp. is a publicly-traded business development company that primarily invests in syndicated bank loans and, to a lesser extent, in debt and equity tranches of collateralized loan obligation (CLO) vehicles [6].

JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high- value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock. ...

Core Viewpoint - AIM ImmunoTech Inc. has announced a public offering of 2,000,000 shares of common stock and accompanying warrants, aiming to raise approximately $8.0 million before expenses [1]. Group 1: Offering Details - The public offering includes 2,000,000 shares of common stock or pre-funded warrants, along with Class E and Class F warrants, each allowing the purchase of up to 2,000,000 shares [1]. - The combined public offering price is set at $4.00 per share or $3.999 per pre-funded warrant, with warrants exercisable immediately upon issuance [1]. - Class E warrants will expire five years after issuance, while Class F warrants will expire eighteen months after issuance [1]. - The closing of the offering is expected around July 30, 2025, pending customary closing conditions [1]. Group 2: Financial and Regulatory Information - Gross proceeds from the offering are anticipated to be approximately $8.0 million before deducting placement agent fees and offering expenses [1]. - The offering is conducted under a registration statement on Form S-1, which was declared effective by the SEC on July 28, 2025 [3]. Group 3: Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [5]. - The company's lead product is Ampligen® (rintatolimod), a first-in-class investigational drug with broad-spectrum activity in clinical trials [5].

Core Viewpoint - Abivax SA has successfully closed a public offering of 11,679,400 American Depositary Shares (ADSs), raising approximately $747.5 million, which will support its operations and clinical trials through 2027 [1][2]. Group 1: Offering Details - The public offering included the full exercise of the underwriters' option, resulting in gross proceeds of approximately $747.5 million, or €637.5 million, before expenses [1]. - Estimated net proceeds from the offering, after deducting underwriting commissions and expenses, are approximately $700.3 million, equivalent to €597.2 million [1]. - The offering was managed by Leerink Partners, Piper Sandler & Co., and Guggenheim Securities, with LifeSci Capital as the lead manager [3]. Group 2: Financial Outlook - The company anticipates that the net proceeds, along with existing cash and cash equivalents, will finance operations into the fourth quarter of 2027, providing a 12-month cash runway post-NDA submission for Ulcerative Colitis, contingent on positive Phase 3 trial results [2]. Group 3: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response for chronic inflammatory diseases, with its lead drug candidate, obefazimod (ABX464), currently in Phase 3 trials for ulcerative colitis [5].

Core Viewpoint - Abivax SA has announced a public offering of American Depositary Shares (ADSs) priced at $64.00 per ADS, aiming to raise approximately $650 million to support its clinical development efforts [1][9][10]. Offering Details - The offering consists of 10,156,000 ADSs, each representing one ordinary share with a nominal value of €0.01 [1]. - The offering price reflects a 21.0% premium over the volume weighted average price of the ordinary shares on Euronext Paris over the last three trading sessions prior to pricing [2]. - The offering is managed by Leerink Partners, Piper Sandler & Co., and Guggenheim Securities, with LifeSci Capital as the lead manager [3]. Financial Proceeds - The gross proceeds from the offering are expected to be approximately $650 million, or €554 million, before deducting expenses [9]. - If the underwriters' option to purchase additional shares is fully exercised, total gross proceeds could reach approximately $747.5 million, or €637.5 million [10]. Use of Proceeds - The company plans to use the net proceeds to fund clinical development for its lead drug candidate, obefazimod, targeting ulcerative colitis and Crohn's disease, as well as for general corporate purposes [11][16]. - Specific allocations include approximately $140 million to $185 million for ulcerative colitis, and $30 million to $65 million for Crohn's disease [16]. Closing and Lock-up - The offering is expected to close on July 28, 2025, subject to customary conditions [6]. - Company board members and executive officers are subject to a 60-day lock-up period following the final prospectus supplement [13]. Dilution Impact - The issuance of ADSs will result in a dilution of approximately 16.0% of the company's share capital on a non-diluted basis, increasing to 18.4% if the underwriters' option is exercised [14]. Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in chronic inflammatory diseases, with its lead candidate currently in Phase 3 trials for ulcerative colitis [20].

Core Viewpoint - Abivax SA has announced the launch of a public offering of approximately $400 million, aimed at funding its clinical development and operational needs [1][10]. Group 1: Offering Details - The public offering will consist of American Depositary Shares (ADSs), each representing one ordinary share of the company, with a nominal value of €0.01 per share [1]. - The company plans to grant underwriters a 30-day option to purchase additional ADSs, up to 15% of the total number proposed to be sold [1]. - The offering price will be determined through a book-building process, and the final amount and terms will be announced after pricing [4][7]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to be allocated as follows: approximately 23% for the development of obefazimod for Ulcerative Colitis, approximately 5% for Crohn's Disease, and about 72% for working capital and general corporate purposes [10][14]. Group 3: Company Background - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases [18]. - The lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis [18]. Group 4: Financial Position - As of June 30, 2025, the company had cash and cash equivalents of $71.4 million, which is expected to finance its operating cash flow requirements into the fourth quarter of 2025 [9].